Remove Chronic Pain Remove Epilepsy Remove Events Remove Topical
article thumbnail

Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children

Cannabis Law Report

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Christopher M. Betsy Brod.

article thumbnail

Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

Cannabis Law Report

(“Virpax”), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10 th through Thursday, January 13 th starting at 7:00 a.m. Event: Virpax Pharma Presentation at the H.C.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Everything You Need To Know About Medical Marijuana Dispensaries In Virginia

MMJ Recs

These include, but are not limited to, cancer, glaucoma, HIV/AIDS, Parkinson’s disease, and epilepsy. Dispensaries typically offer a variety of products, including flower, concentrates, edibles, tinctures, and topicals. Additionally, dispensaries may run promotional events or offer loyalty programs to reward regular customers.

article thumbnail

Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Cannabis Law Report

About Epoladerm™ Virpax Pharmaceuticals is developing Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee. For more information, please visit www.virpaxpharma.com.

article thumbnail

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

Cannabis Law Report

About Epoladerm™ Virpax Pharmaceuticals is developing Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee. For more information, please visit www.virpaxpharma.com.

article thumbnail

Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement

Cannabis Law Report

The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. In October 2021, Virpax announced that a $1.87 Forward-Looking Statement.

article thumbnail

Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

Cannabis Law Report

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Epoladerm™ Epoladerm is a diclofenac topical spray film product candidate that is being developed for pain associated with osteoarthritis of the knee.